5(6)-nitro-1-(1,1-dissociator-3)-2-chlorobenzimidazole displaying biological activity

 

The invention relates to organic chemistry and medicine, in particular to a new connection - 5(6)-nitro-1-(1,1-dissociator-3)-2-chlorobenzimidazole formula I, manifesting antispasmodic and bronchodilator activity. The invention expands the Arsenal antispasmodic and bronchodilator funds with low toxicity. 2 C.p. f-crystals, 4 PL.

The present invention relates to medicine, namely to pharmacology, and can be used to produce new skin and bronchodilators.

The technical result - expanding Arsenal of biologically active substances, including having spasmolytic and bronchodilator activity.

The essence of the invention: 5(6)-nitro-1-(1,1-dissociator-3)-2-chlorobenzimidazole (1) formulashowing antispasmodic and bronchodilator activity.

As comparative drugs taken reference bronholitin aminophylline (ethylendiamine salt of 1,3-dimethylxanthine), cholinolytic platifillin (3-ethylidene-6-hydroxy-5,6-dimethylpyridine-1,8-dioxocyclohexa[2,3,4-gh] pyrrolizine-2,7-dione hydrotartrate), myotropic spasmolysant papaverine (1-[(3,4-DemeTech described in numerous scientific papers (Gusel C. A., Sicilian A. D., Smirnov, D. P. //Pediatrics. - 1990. - 7. - S. 52-54. Saudi F. S. //Pharmacol. and toxicol. - 1985.- 5.-S. 105-108. Slutsky, M. E. Aminophylline. - M.: Medgiz, 1960. Chuchalin A. G., Kamenova C. A., Kukes Century, etc. //Ter. Arch. - 1989. - 8. - S. 30-37. Hazura centuries, Saratikov A. S. Pharmacological agents in experimental medicine and biology, Tomsk, 1977, S. 39).

The inventive compound is synthesized as follows.

Interaction 5(6)-nitro-2-chlorobenzimidazole with epimyocardium in an alkaline environment get 5(6)-nitro-1-(titanyl-3)-2-chlorobenzimidazole, which by oxidation with potassium permanganate solution in the environment of glacial acetic acid turn 5(6)-nitro-1-(1,1-dissociator-3)-2-chlorobenzimidazole.

Example 1. The synthesis of the claimed compounds 5(6)-Nitro-2-chlorobenzimidazole 9.88 g (50 mmol) dissolved in 22 ml of 10% sodium hydroxide solution. To the solution at a temperature of 30-35oWith added 6.0 g (55 mmol) of aetiocholanolone and stirred for 1 hour. The crystalline precipitate is filtered off, washed with diethyl ether, water, dried at 60oC. Get to 2.29 g (85%) 5(6)-nitro-1-(titanyl-3)-2-chlorobenzimidazole purify by crystallization from a mixture of ethanol-water (1:1).

The IR spectrummaxcm-1: 750 and 845 (C-NO2), 1350 and 1522 (NO2), 1470 (C=N) WITH THE 1H, NCH) of 7.7-8.7 m (3H, H-arene.) Elemental analysis
Found, %: C 44,15 N 3,30 N 13,85 S 12,04 - C10H8N3ClO2S
Calculated, %: C 44,52 N 2,96 N 15,58 S 11,80
To a solution of 5.4 g (20 mmol) 5(6)-nitro-1-(titanyl-3)-2-chlorobenzimidazole in 300 ml of glacial acetic acid are added dropwise within 30 minutes 9,48 g of potassium permanganate (60 mmol) in 150 ml of water. The mixture is stirred at a temperature of 30o2 h, add 500 g of ice and stirred for 1 h, then a solution discolor with saturated solution of sodium thiosulfate. The formed precipitate is filtered off, washed with water and dried. Obtain 4.7 g (78%) of compound (I). Purify by crystallization from n-butanol.

The IR spectrummaxcm-1: 753 and 845 (C-NO2), 1165 and 1298 (SO2), 1350 and 1527(NO2),1480(C=N).

Elemental analysis
Found, %: 39.9 N 2.6 N S 13,7 10,5 - C10H8N3O4SCl
Calculated, %: C 39,80 N 2,65 N 13,93 S 10,61
The inventive compound is a yellow crystalline powder, soluble in dimethylsulfoxide, dimethylformamide.

Example 2. Acute toxicity of the claimed compounds.

Acute toxicity was determined after intragastric and intraperitoneal administration weinbrenner mice-males according to the method of J. Litchfield and F. Wilcoxon modification Rota (Bolotnyh observed for 14 days. The results are shown in table 1.

As can be seen from table 1, the claimed connection with the introduction into the stomach belongs to the 3rd class of hazard - moderate hazard (N. F. Izmerov, I. C. Sanotski, K. K. Sidorov. Options toxicometric industrial poisons single exposure (reference). //M Medicine, 1977). Substance intraperitoneal injection is low toxic (Sidorov, K. K. Toxicology of new industrial chemical substances. //Vol.13, L. Medicine, 1973. - S. 47-51).

Example 3. Antispasmodic activity
Spasmolytic activity of the claimed compounds was studied on the preparation of smooth muscle of the isolated intestine of the rat [the Biogenesis of natural compounds. /Under. ed L. M. Hindman. - M., 1965.- C. - 581-588]. The experiments were carried out in thermostated at 37oWith aerated by air bath volume of 50 ml with a solution of ringer-Locke. The reduction of smooth muscles caused by adding karbaholina (1:100000) or barium chloride (1:5000) and registered under isotonic conditions, the duration of exposure of spasmogens and connection was 2 minutes

As a result of researches it is established that the claimed compound has no effect on the initial tone of smooth muscles of the intestine of the rat, but causes pronounced snijanafleur connection re-introduction karbaholina does not cause spasms of the intestine, indicating the presence of an anticholinergic action.

The claimed compound has a myotropic antispasmodic effect, as evidenced by the decrease spasm caused by barium chloride (table 3).

Example 4. Bronchodilatory activity
Bronchodilatory activity of the synthesized compounds was studied in anesthetized (Nembutal, 40 mg/kg, intraperitoneally) and correzioni (myorelaxing 1 mg/kg) cats weight of 2.3 and 3.4 kg of the bronchial Tone was detected by methods Concetta and Rosler modification So M Turpaeva (Turpaev So M //Fiziol. Journe. Of the USSR. - 1953. , 39, 6. - S. - 732-734).

Experimental bronchospasm caused by proserin (0.25 mg/kg) and karbaholina (5 µg/kg). The claimed compound was administered at a dose of from 1/10 LD50in suspension (tween-60) of isotonic sodium chloride and used for comparison of aminophylline dose of 8 mg/kg (ED50) in aqueous solution (Yu Century Strokin, F. S. of Sarudi, A. A., Kremser, N. M.Nazipov etc. //Synthesis, transformation and biological properties of 7,8-disubstituted xantina/ //Chem. Pharm. log. - 5. - S. 566-569).

The influence of the proposed connection on the tone of bronchi are presented in table 4.

Presents the chemical compound has a mechanism of spasma,3 times less toxic.


Claims

1. 5 (6)-Nitro-1-(1,1-dissociator-3)-2-chlorobenzimidazole formulas

2. Substance under item 1, have antispasmodic activity.

3. Substance under item 1, with bronchodilator activity.

 

Same patents:

The invention relates to 4-hydroxy-3-chinainternational and hydrazides of General formula (I), where a represents a-CH2- or-NH-, a R1, R2, R3and R4such as defined in the claims

The invention relates to new compounds of the mixture of isomers of 2-monoethanolamine-5(6)-nitro-1-(titanyl-3)benzimidazole of the formula I

The invention relates to tricyclic condensed heterocyclic compounds of the formula I, X is, for example, CH, CH2, СНR (where R means a lower alkyl group or a substituted lower alkyl group) or CRR' (where R and R' have the values specified above for R); Y means, for example, CH, CH2or C=O; z means, for example, S, S=O=; U denotes C; R1-R4independent means, for example, a hydrogen atom, SR (where R has the above values), phenyl group, substituted phenyl group, follow group, thienyl group, benzofuran or benzothiazyl at least one element of R5and R8means, for example, HE and the rest of the elements of R5and R8independent means, for example, a hydrogen atom; and their optical isomers, conjugates, and pharmaceutically acceptable salts

The invention relates to sulphonilecarbomide acids of the formula

< / BR>
and/or their stereoisomeric forms and/or physiologically acceptable salts, where R1means phenyl, phenyl, one or twice substituted by a group WITH1-C6-alkyl-Oh, halogen, trifluoromethyl, a group WITH1-C6-alkyl-O-C(O)-, methylenedioxy-, R4-(R5)N-; triazole, thiophene, pyridine; R2means H, C1-C6alkyl; R4and R5are adnikowymi or different and denote H, C1-C6-alkyl; R3means H, C1-C10-alkyl, where alkyl unsubstituted and/or one hydrogen atom of the alkyl residue substituted by hydroxyl,2-C10alkenyl, R2-S(O)n-C1-C6-alkyl, where n means 0, 1, 2; R2-S(O)(=NH)-(C1-C6)-alkyl and the other, or R2and R3together form a cycle with a carboxyl group as a substituent cycle of partial formula II:

< / BR>
where r is 0, 1, 2, 3 and/or one of the carbon atoms in the cycle replaced by-O-, and/or the carbon atom in the cycle part of the formula II substituted once by phenyl; a represents a covalent bond, -O-;

The invention relates to new non-steroidal compounds which are high-affinity modulators of steroid receptors

The invention relates to amide derivative of the General formula I, the symbols in the formula have the following meanings: D is pyrazolidine group which may have 1-3 halogenated derivatives or unsubstituted lower alkyl group as the Deputy(I)her is fenelonov or topendialog group, X represents a group of formula-NH-CO - or-CO-NH -, and a represents a phenyl group which may be substituted by one or more halogen atoms, or a five - or six-membered monocyclic heteroaryl group which may be substituted by one or more of lower alkyl groups

The invention relates to the field of production of new heterocyclic o-dicarbonitriles formula I

< / BR>
< / BR>
< / BR>
< / BR>
< / BR>
o-Dicarbonitrile can be used to obtain hexatriene-fluorophores, as a fragment of the donor to obtain hexatriene-bifluorophors besed and hexatriene-trifluoroprop

The invention relates to new derivatives of benzimidazole of formula 1, where R1represents hydrogen or hydrocarbon group with a short chain, R2- CH2HE, COOH, СООR34,4-dimethyl-2-oxazoline

The invention relates to new chemical compounds, namely bis-Quaternary salts of benzimidazole formula

< / BR>
where In= N, CH3R= alkyl, IN1=N, CH3, Cl, co3m=0-8, n=0-2, X=residue of formula

< / BR>
where Y= NH, O, B=H, H, CL, which may find application as antivalent-stabilizer for silver halide photographic emulsions sensitized carbocyanine dyes, as well as to methods of sensitizing silver halide emulsions and their use

The invention relates to 2-/2-imidazolin-2-yl/benzoheterocycles compounds, which have the following structure:

< / BR>
in which: R1is hydrogen, CI/C1-C4/ alkylamino,

C1-C12the alkyl may be substituted by one to three substituents: C1-C4alkoxy, C1-C4alkylthio, halogen, hydroxy, C1-C4cycloalkyl, benzoyloxy, fullam, phenyl, possibly substituted by nitro, one to three halogen, C1-C4alkyl groups or C1-C4alkoxy groups, carboxy, C1-C4alkoxycarbonyl, cyano or three/C1-C4/ alkylammonium a halide;

C3-C12alkenyl may be substituted by one to three substituents: C1-C4alkoxy, phenyl, halogen or C1-C4alkoxycarbonyl;

C3-C6cycloalkyl, can be substituted one to three C1-C4alkyl groups;

C3-C16the quinil may be substituted by one to three halogen or a cation;

R2is C1-C4by alkyl;

R3is C1-C4the alkyl or C3-C6cyclo is the best C1-C4cycloalkyl possibly replaced by stands;

B is hydrogen, COR4or SO2R5with the proviso that when B is COR4or SO2R5, R1is other than hydrogen or a cation, and R9different from hydrogen;

R4is C1-C11the alkyl, chlorochilon or phenyl, possibly substituted with halogen, nitro or C1-C4by alkyl;

R5is C1-C4the alkyl or phenyl, possibly substituted C1-C4by alkyl;

X, Y and Z each independently is CR6, CR7R8, N or NR9with the proviso that at least one of X, Y and Z must be N or NR9;

configuration is either a simple bond or double bond with the proviso that when any of X, Y or Z is CR7R8or NR9then === configuration, attached to it, is a simple connection, with one proviso that at least one of the === configuration represents a simple bond;

R6, R7and R8are independently hydrogen, halogen, C1-C4alkoxy or C1-C4the alkyl may be substituted one is;

R9is hydrogen or C1-C4the alkyl possibly substituted by hydroxy or one to three halogen, C1-C4alkoxy groups, or C1-C4alkylthio groups;

Q is hydrogen, halogen, C1-C4alkoxy or C1-C4the alkyl, possibly substituted by one to three of the following substituents: halogen, C1-C4alkoxy, C1-C4alkylthio or C2-C4alkenyl;

their optical isomers, when R2and R3not the same or when R7and R8unequal;

their tautomers and geometric isomers, and their attached salts of acids, except when R1is salabrasion cation

The invention relates to chemical-pharmaceutical industry, namely to new biologically active substances on the basis of which can be created drugs with hypotensive and analepticheskih activity

The invention relates to new derivatives thioxanthine General formula

< / BR>
where R is C6H5(1a), CH2-CH=CH2, (1b)

compounds according to the invention have greater inflammatory and bronchodilatory activity than aminophylline, being less toxic
The invention relates to medicine

The invention relates to medicine and can be used in the practice of Spa and medical institutions
Up!